EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials

Yingjie Qiu iD, Yan Han, Beibei Guo iD

Statistics in Medicine · 2026

DOI: 10.1002/sim.70357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von Yingjie Qiu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Immunotherapy, Biomarkers, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Indiana Clinical and Translational Sciences Institute, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In immunotherapy, both the dose and the schedule of drug administration can significantly influence therapeutic effects by modulating immune system activation. Incorporating immune response measures into clinical trial designs offers an opportunity to enhance decision‐making by leveraging their close association with therapeutic efficacy and toxicity. Motivated by settings where biomarker data indicate improved efficacy in biomarker‐positive patients, we propose a dose–schedule optimization strategy tailored to each biomarker‐defined subgroup, based on elicited utility functions that capture risk‐benefit tradeoffs. We introduce a joint modeling framework that simultaneously evaluates immune response, toxicity, and efficacy, enabling information sharing across outcome types and patient subgroups. Our approach utilizes parsimonious yet flexible models designed specifically to address challenges due to small sample sizes commonly encountered in early‐phase trials. Simulation studies demonstrate that the proposed design achieves desirable operating characteristics and effectively informs dose–schedule optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyBiomarkersClinical Trials as TopicHumansComputer SimulationBayes TheoremDrug Administration ScheduleResearch DesignModels, StatisticalDose-Response Relationship, Drug

Stichwörter der Autor:innen

Bayesian adaptive designbiomarkerimmunotherapyoptimal treatment regimephase I/II trialrisk‐benefit tradeoffsubgroups

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
  • Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.

ORCID-Profile: Yingjie Qiu, Beibei Guo

Förderung

  • NCI NIH HHS
  • Indiana Clinical and Translational Sciences Institute
  • National Cancer Institute

Zitieren

APA

Qiu, Y., Han, Y., & Guo, B. (2026). A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70357

Vancouver

Qiu Y, Han Y, Guo B. A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70357

BibTeX
@article{Qiu2026,
  author = {Qiu, Yingjie and Han, Yan and Guo, Beibei},
  title = {A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70357}
}
Kostenlos starten →